硕世生物2025年度归母净亏损3971.03万元

Core Viewpoint - The company reported a total operating revenue of 340 million yuan for the year 2025, reflecting a year-on-year decline of 2.64% and a net loss attributable to the parent company of 39.71 million yuan, alongside a net loss of 104 million yuan after deducting non-recurring gains and losses [1] Group 1: Financial Performance - The total operating revenue for 2025 was 340 million yuan, which is a decrease of 2.64% compared to the previous year [1] - The net loss attributable to the parent company was 39.71 million yuan [1] - The net loss after deducting non-recurring gains and losses was 104 million yuan [1] Group 2: Business Environment - The company's main business showed stable development during the reporting period [1] - The decline in revenue from self-produced diagnostic reagent products was influenced by intensified industry competition and the ongoing implementation of centralized procurement in the medical sector [1] - An adjustment in the value-added tax rate for self-produced diagnostic reagents to 13% also contributed to the revenue decline [1]